Aptus Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.74M Sell
134,318
-8,713
-6% -$500K 0.05% 275
2026
Q1
$8.67M Buy
143,031
+77,138
+117% +$4.5M 0.07% 248
2025
Q4
$3.55M Buy
65,893
+4,419
+7% +$213K 0.03% 369
2025
Q3
$2.77M Sell
61,474
-4,077
-6% -$190K 0.02% 388
2025
Q2
$3.03M Sell
65,551
-246,308
-79% -$12.1M 0.02% 362
2025
Q1
$19M Buy
311,859
+24,653
+9% +$1.44M 0.2% 109
2024
Q4
$16.2M Buy
287,206
+265,468
+1,221% +$14.8M 0.17% 114
2024
Q3
$1.12M Buy
21,738
+4,421
+26% +$207K 0.02% 390
2024
Q2
$719K Buy
17,317
+559
+3% +$25K 0.01% 446
2024
Q1
$909K Buy
16,758
+2,305
+16% +$117K 0.02% 408
2023
Q4
$742K Sell
14,453
-43,854
-75% -$2.3M 0.02% 325
2023
Q3
$3.38M Buy
58,307
+932
+2% +$57.1K 0.09% 168
2023
Q2
$3.67M Sell
57,375
-3,274
-5% -$220K 0.09% 174
2023
Q1
$4.2M Buy
60,649
+16,904
+39% +$1.19M 0.11% 137
2022
Q4
$3.15M Buy
43,745
+3,222
+8% +$243K 0.1% 172
2022
Q3
$2.88M Buy
40,523
+1,307
+3% +$94.8K 0.07% 162
2022
Q2
$3.02M Buy
39,216
+30,978
+376% +$2.36M 0.08% 145
2022
Q1
$606K Buy
+8,238
New +$553K 0.02% 287
2020
Q3
Sell
-47,750
Closed -$2.81M 471
2020
Q2
$2.81M Buy
47,750
+4,020
+9% +$240K 0.18% 82
2020
Q1
$2.44M Buy
43,730
+5,250
+14% +$321K 0.21% 78
2019
Q4
$2.45M Buy
38,480
+9,158
+31% +$524K 0.17% 123
2019
Q3
$1.49M Buy
+29,322
New +$1.38M 0.08% 141

Other funds holding BMY

Aptus Capital Advisors's BMY Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 6.1% in Q2 2026, selling an estimated $500K and leaving 134,318 shares worth $7.74M. The position accounts for 0.05% of the portfolio, ranked #275.

Aptus Capital Advisors first reported a position in BMY in Q3 2019 and has held it in 22 quarters since. The position peaked at $19M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Aptus Capital Advisors held 134,318 shares of Bristol-Myers Squibb worth $7.74M as of Q2 2026.
  • Aptus Capital Advisors sold 8,713 Bristol-Myers Squibb shares in Q2 2026, an estimated $500K.
  • Bristol-Myers Squibb made up 0.05% of Aptus Capital Advisors's portfolio in Q2 2026, its #275 holding.
  • Aptus Capital Advisors first reported a position in Bristol-Myers Squibb in Q3 2019 and has held it in 22 quarters since.
  • Aptus Capital Advisors's Bristol-Myers Squibb position peaked at $19M in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.